论文部分内容阅读
目的探究多西他赛结合噻替哌对乳腺癌组织中上皮间质转化分子标志物及Beclin 1的影响。方法选取2010年8月-2015年1月该院收治的浸润性乳腺癌患者85例,根据随机对照表法分为观察组与对照组,其中观察组患者43例,接受多西他赛联合噻替哌化疗;对照组患者42例,接受多西他赛化疗。以3周为1个化疗周期,两组完成3个周期的化疗后再进行手术治疗。分析两组疗效、不良反应、治疗前后乳腺癌组织中上皮间质转化分子标志物及Beclin 1 mRNA和蛋白表达变化。结果观察组临床疗效分级显著优于对照组(U=2.18,P=0.029),同时观察组患者客观缓解率(ORR)显著优于对照组(χ~2=4.24,P=0.040),两组间疾病控制率(DCR)比较,差异无统计学意义(χ~2=1.99,P=0.159)。对照组患者在白细胞减少、中性粒细胞减少、贫血及血小板减少等化疗不良反应方面显著优于观察组(P=0.000、0.000、0.000、0.001),而两组恶心呕吐、腹泻及肝脏损伤方面比较,差异无统计学意义(P=0.074、0.655、0.101)。治疗后所有患者Beclin 1、E-cadherin mRNA及蛋白表达与治疗前比较均上调(t=3.584、5.201、3.263、5.831,P=0.006、0.000、0.001、0.000),N-cadherin mRNA及蛋白表达与治疗前比较显著下调(t=3.127、5.175,P=0.008、0.000),而观察组Beclin 1、E-cadherin mRNA、蛋白表达上调及N-cadherin mRNA、蛋白表达下调的程度均大于对照组(t=4.281、5.682、6.388,P=0.000、0.000、0.000)。结论多西他赛结合噻替哌对乳腺癌患者的临床疗效更显著,同时可上调Beclin 1、E-cadherin,下调N-cadherin的表达来阻断乳腺癌细胞的转移,但同时多西他赛联合噻替哌化疗的不良反应也更为严重。
Objective To investigate the effect of docetaxel combined with thiotepa on epithelial-mesenchymal transition molecular marker and Beclin 1 in breast cancer. Methods Eighty-five patients with invasive breast cancer admitted to our hospital from August 2010 to January 2015 were divided into observation group and control group according to the randomized controlled table. Among them, 43 patients in the observation group received docetaxel plus thiophene Twenty-four patients in the control group received docetaxel chemotherapy. Three weeks for a chemotherapy cycle, two cycles of chemotherapy completed after three cycles of surgery. The curative effect, adverse reaction and the expression of Beclin 1 mRNA and protein in epithelial-mesenchymal transition in breast cancer tissues before and after treatment were analyzed. Results The clinical efficacy of the observation group was significantly better than that of the control group (U = 2.18, P = 0.029). The objective response rate (ORR) of the observation group was significantly better than that of the control group (χ ~ 2 = 4.24, There was no significant difference in DCR (χ ~ 2 = 1.99, P = 0.159). The patients in the control group were significantly better than the observation group in adverse reactions such as leukopenia, neutropenia, anemia and thrombocytopenia (P = 0.000,0.000,0.000,0.001), but nausea and vomiting, diarrhea and liver damage in both groups The difference was not statistically significant (P = 0.074,0.655,0.101). The mRNA and protein expressions of Beclin 1, E-cadherin in all the patients after treatment were all significantly up-regulated compared with those before treatment (t = 3.584,5.201,3.263,5.831, P = 0.006,0.000,0.001,0.000) (T = 3.127,5.175, P = 0.008, 0.000). The mRNA and protein expressions of Beclin 1 and E-cadherin in the observation group and the levels of N-cadherin mRNA and protein in the observation group were significantly lower than those in the control group (t = 4.281, 5.682, 6.388, P = 0.000, 0.000, 0.000). Conclusion Docetaxel combined with streptozotocin has a more significant clinical effect on breast cancer patients, up-regulating Beclin 1, E-cadherin and down-regulating the expression of N-cadherin to block the metastasis of breast cancer cells. However, docetaxel Side effects of thiazide combined chemotherapy are more serious.